Literature DB >> 26305237

Coagulopathy of Acute Sepsis.

Nicola Semeraro1, Concetta T Ammollo1, Fabrizio Semeraro1, Mario Colucci1.   

Abstract

Coagulopathy is common in acute sepsis and may range from subclinical activation of blood coagulation (hypercoagulability), which may contribute to venous thromboembolism, to acute disseminated intravascular coagulation, characterized by widespread microvascular thrombosis and consumption of platelets and coagulation proteins, eventually causing bleeding. The key event underlying this life-threatening complication is the overwhelming inflammatory host response to the pathogen leading to the overexpression of inflammatory mediators. The latter, along with the microorganism and its derivatives drive the major changes responsible for massive thrombin formation and fibrin deposition: (1) aberrant expression of tissue factor mainly by monocytes-macrophages, (2) impairment of anticoagulant pathways, orchestrated by dysfunctional endothelial cells (ECs), and (3) suppression of fibrinolysis because of the overproduction of plasminogen activator inhibitor-1 by ECs and thrombin-mediated activation of thrombin-activatable fibrinolysis inhibitor. Neutrophils and other cells, upon activation or death, release nuclear materials (neutrophil extracellular traps and/or their components such as histones, DNA, lysosomal enzymes, and High Mobility Group Box-1), which have toxic, proinflammatory and prothrombotic properties thus contributing to clotting dysregulation. The ensuing microvascular thrombosis-ischemia significantly contributes to tissue injury and multiple organ dysfunction syndromes. These insights into the pathogenesis of sepsis-associated coagulopathy may have implications for the development of new diagnostic and therapeutic tools. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26305237     DOI: 10.1055/s-0035-1556730

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  28 in total

1.  Response.

Authors:  David Kaplan; Matthew T Rondina
Journal:  Chest       Date:  2016-04       Impact factor: 9.410

2.  Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis.

Authors:  Allan J Walkey; Emily K Quinn; Michael R Winter; David D McManus; Emelia J Benjamin
Journal:  JAMA Cardiol       Date:  2016-09-01       Impact factor: 14.676

3.  D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.

Authors:  Fabrizio Semeraro; Concetta T Ammollo; Pietro Caironi; Serge Masson; Roberto Latini; Mauro Panigada; Antonio Pesenti; Nicola Semeraro; Luciano Gattinoni; Mario Colucci
Journal:  Blood Transfus       Date:  2019-11-19       Impact factor: 3.443

4.  A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC.

Authors:  Toshiaki Iba; Marcello Di Nisio; Jecko Thachil; Hideo Wada; Hidesaku Asakura; Koichi Sato; Daizoh Saitoh
Journal:  Clin Appl Thromb Hemost       Date:  2017-07-27       Impact factor: 2.389

5.  The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients.

Authors:  Ronit Mor-Cohen; Michal Zucker; Colin Grissom; Samuel M Brown; Uri Seligsohn; Robert A Campbell; Antoinette M Blair; Matthew T Rondina
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

6.  Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin.

Authors:  Syed M Qadri; David A Donkor; Varsha Bhakta; Louise J Eltringham-Smith; Dhruva J Dwivedi; Jane C Moore; Laura Pepler; Nikola Ivetic; Ishac Nazi; Alison E Fox-Robichaud; Patricia C Liaw; William P Sheffield
Journal:  J Cell Mol Med       Date:  2016-01-19       Impact factor: 5.310

7.  Enzymatic Synthesis of Chondroitin Sulfate E to Attenuate Bacteria Lipopolysaccharide-Induced Organ Damage.

Authors:  Jine Li; Erica M Sparkenbaugh; Guowei Su; Fuming Zhang; Yongmei Xu; Ke Xia; Pen He; Sultan Baytas; Shannon Pechauer; Anand Padmanabhan; Robert J Linhardt; Rafal Pawlinski; Jian Liu
Journal:  ACS Cent Sci       Date:  2020-07-01       Impact factor: 14.553

Review 8.  The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects.

Authors:  Nicola Semeraro; Mario Colucci
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

9.  Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice.

Authors:  Charles E Bane; Ivan Ivanov; Anton Matafonov; Kelli L Boyd; Qiufang Cheng; Edward R Sherwood; Erik I Tucker; Stephen T Smiley; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

Review 10.  2017 WSES guidelines for the management of iatrogenic colonoscopy perforation.

Authors:  Nicola de'Angelis; Salomone Di Saverio; Osvaldo Chiara; Massimo Sartelli; Aleix Martínez-Pérez; Franca Patrizi; Dieter G Weber; Luca Ansaloni; Walter Biffl; Offir Ben-Ishay; Miklosh Bala; Francesco Brunetti; Federica Gaiani; Solafah Abdalla; Aurelien Amiot; Hany Bahouth; Giorgio Bianchi; Daniel Casanova; Federico Coccolini; Raul Coimbra; Gian Luigi de'Angelis; Belinda De Simone; Gustavo P Fraga; Pietro Genova; Rao Ivatury; Jeffry L Kashuk; Andrew W Kirkpatrick; Yann Le Baleur; Fernando Machado; Gustavo M Machain; Ronald V Maier; Alain Chichom-Mefire; Riccardo Memeo; Carlos Mesquita; Juan Carlos Salamea Molina; Massimiliano Mutignani; Ramiro Manzano-Núñez; Carlos Ordoñez; Andrew B Peitzman; Bruno M Pereira; Edoardo Picetti; Michele Pisano; Juan Carlos Puyana; Sandro Rizoli; Mohammed Siddiqui; Iradj Sobhani; Richard P Ten Broek; Luigi Zorcolo; Maria Clotilde Carra; Yoram Kluger; Fausto Catena
Journal:  World J Emerg Surg       Date:  2018-01-24       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.